In the concept of the aesthetic formation of knowledge and its as soon as possible and success-oriented application, insights and profits without the reference to the arguments developed around 1900. The main investigation also includes the period between the entry into force and the presentation in its current version. Their function as part of the literary portrayal and narrative technique.
Introduction
N, N-Dimethylformamide dimethyl acetal (DMFDMA) also known as 1, 1-dimethoxy-N, N-dimethylmethylamine or 1, 1-dimethoxytrimethylamine, as its name indicates, is a derivative of formamide [1] acts as methylating and formylating agent. Formylated products obtained by treating compounds with active methylene group and DMFDMA have proved to be very useful intermediates in the synthesis of heterocycles [1] [2] [3] [4] . Enaminone derivatives have been proven to be valuable synthon for the synthesis of a wide variety of biologically active heterocycles [4] . On the other hand, the functionalized acridines are often used to design and synthesize the compounds with various pharmacological activities such as antibacterial [5] , antifungal [5] , anti-inflammatory [6] , anticancer [7] , anti-cytotoxic [8] and anti-malarial activities [9] . Though the synthesis of enaminone and its derivatives from simple ketones using DMFDMA are available in the literature, only a very few reports are available on the enaminones from active methylene of the various heterocycles [1-4 and 10-14] . This prompted us to attempt the present work in which we have used the active methylene group of 3,4-dihydro-9-arylacridin-1(2H)-ones to synthesize the corresponding enaminone which in turn used as a synthon to obtain the corresponding pyrazole, isoxazole and 1-aryl-1H-pyrazole using hydrazine, hydroxylamine, phenylhydrazine respectively.
Ethical approval: The conducted research is not related to either human or animal use.
Materials and Methods
Melting points (mp) reported in this work are recorded in Elchem microprocessor based DT apparatus in open capillary tubes and are uncorrected. 1 H NMR and 13 C NMR are recorded in Bruker 400 MHz NMR spectrometer with TMS as an internal reference. The chemical shift values are reported in parts per million (δ, ppm) from internal standard TMS. High-Resolution Mass spectra were recorded using Bruker MaXis HR-MS (ESI-Q-TOF-MS) instrument. All the reagents were purchased from Aldrich and used as received. Excess solvents were removed under vacuum. Organic extracts were dried with anhydrous Na 2 SO 4 . Silica gel 60F 254 aluminum sheets were used in analytical thin-layer chromatography. Visualization of spots on TLC plates was effected by UV illumination, exposure to iodine vapour and heating the plates dipped in a KMnO 4 stain. In column chromatography, the silica gel with 230-400 mesh size was used for the purification.
General procedure for the synthesis of 3,4-dihydro-9-arylacridin-1(2H)-ones.
The 2-amino benzophenone 1a (0.1 g, 0.0005 M) was treated with 1,3-cyclohexanedione (0.06 g, 0.0005 M) in presence of ortho-phosphoric acid (catalyst) in ethanol and refluxed for 12 hrs. After the completion of the reaction the crude was poured into ice cold water and the formed precipitate was filtered and dried to afford the product 2a. The obtained product was used without further purification. And the procedure was repeated with 1b-c to get 2b-c. 
3,4-dihydro-9-phenylacridin-1(2H)-one (2a)
Yellow
7-chloro-3,4-dihydro-9-phenylacridin-1(2H)-one (2b)
General procedure for synthesis of (E)-2-((dimethylamino)methylene)-3,4-dihydro-9-arylacridin-1(2H)-ones (3a-c)
A mixture of 3,4-dihydro-9-phenylacridin-1(2H)-one (0.1g, 0.0005 M) 2a-c with DMFDMA (0.1 mL, 0.0005 M) in toluene (5 mL) and refluxed for 8-10 hrs to afford the product 3a.
The mixture was then evaporated under reduced pressure to afford the solid, which was filtered, washed with hexane and then dried. The similar procedure was repeated with 2b-c to get 3b-c. The obtained product used for further analysis without any purification process.
(E)-2-((dimethylamino)methylene)-3,4-dihydro-9-phenylacridin-1(2H)-one (3a)
Colourless solid (yield 86%), m. 
General procedure for the synthesis of 4,5-dihydro-11-aryl-2H-pyrazolo[3,4-a] acridines (4a-c)
A mixture of compound 3a (0.1 g, 0.0003 M), hydrazine hydrate (0.05 mL, 0.0101 M) and 1-2 drops of acetic acid (catalyst) in ethanol (10 mL) was refluxed at 80 °C for 6-8 h. The mixture was then extracted with ethyl acetate, dried over sodium sulphate and concentrated under reduced pressure to afford the crude product 4a. The obtained crude product was purified by silica gel column chromatography using ethylacetate/hexane (4:6) eluent. To check there reproducibility the reaction and to get 4b-c, the procedure was repeated with 3b-c. 
General procedure for the synthesis of 4,5-dihydro-11-phenylisoxazolo[5,4-a] acridines (5a-c)
A mixture of compound 3a (0.1 g, 0.0003 M) in ethanol (10 mL), hydroxyl amine hydrochloride (0.02 g, 0.0003 M) was refluxed at 80°C for 6-8 h. After the completion of the reaction, the reaction mixture was poured into ice water; the obtained crude was filtered, dried to afford the product 5a. The obtained product was purified by silica gel column chromatography using ethylacetate/hexane (4:6) eluent. Similar procedure was adopted with 3b-c to get 5b-c. 
General procedure for the synthesis of 4,5-dihydro-1,11-diaryl-1H-pyrazolo[3,4-a] acridine (6a-c)
A mixture of compound 3a (0.1 g, 0.0003 M), phenyl hydrazine (0.03 g, 0.0003 M) in glacial acetic acid (5 mL), was refluxed at 110°C for 12 h. The reaction mixture was then extracted with DCM, dried over sodium sulphate and concentrated under reduced pressure to afford the crude product 6a. The obtained crude product was purified by silica gel column chromatography using ethylacetate/ hexane (4:6) eluent. To check the reproducibility similar procedure was adopted with 3b-c to get 6b-c. 
9-chloro-4,5-dihydro-1,11-diphenyl-1H-pyrazolo[3,4-a]acridine (6b)
Yellow solid, (yield 58%), m.p: 175-177ºC; 
9-chloro-11-(2-chlorophenyl)-4,5-dihydro-1-phenyl-1H-pyrazolo[3,4-a]acridine (6c)
Brown solid, (yield 59%), m. 
Spectral Characterization
All these newly synthesized compounds 3a-c to 6a-c were characterized using 1 H-NMR, 13 C-NMR, DEPT-135, H, H-COSY, C, H-COSY, HR-MS (ESI) and the data included in the experimental section. Consequently, all the newly derived target molecules 3a-c to 6a-c subjected to the in-vitro anti-fungal, anti-bacterial and antioxidant evaluations and their results were discussed under biological evaluations.
Spectral Characterization of Compound 3c
The compound 3c has been characterized by .7 ppm were due to the non-proton bearing carbons at C-20, C-6, C-3, C-23, C-16, C-2, C-22 and ipso positions. The formation of compound 3c also been supported by the observation of (ESI-HRMS) m/z value at 397.0871 in the mass spectrum.
Spectral Characterization of Compound 4a
The compound 4a has been characterized by 1 H-NMR, 
Spectral Characterization of Compound 5a
The compound 5a has been characterized by has been assigned as a methylene carbon at C-14 and one more signal at d 17.6 ppm represents at C-15. The extreme downfield signal at d 158.1 ppm is assigned to C-2. The signal at d 148.6 ppm has been assigned to the carbon at C-16 due to shielding effect of adjacent functional groups. The C-7 and C-8 carbons were identified as d 130.3 and 130.9 ppm respectively. The aliphatic CH 2 carbons at (C-14 and C-15) carbons were distinguished using DEPT-135 spectrum of the compound. Remaining aromatic carbon attached hydrogen appears from aromatic region from d 148.6 to 125.7 ppm. Similarly, the ortho, meta and para carbons of phenyl group at C-4 were identified as d 129.7, 129.2 and 128.5 ppm respectively. The formation of compound 5a also been supported by the observation of (ESI-HRMS) m/z value at 299.1191 in the mass spectrum.
Spectral Characterization of Compound 6a
The compound 6a has been characterized by 1 H-NMR, 
In-vitro antibacterial studies by micro dilution method
The Where Ac represents intensity of the wells with compound concentration C; Ao represents intensity of the negative control without compound concentrations. Further, minimum inhibitory concentration, MIC (μM) values representing the lowest concentration of the compound which exhibited significant decrease in bacterial viability (>95%) was determined. All the experiments were performed in triplicate and the results were expressed as the average of three independent experiments. The results were given as Table-3 along with the minimum inhibitory concentrations. The compounds exhibited a broad spectrum of antibacterial activity against the tested Gram-positive bacterial pathogens.
In-vitro antioxidant activity by DPPH free radical scavenging method
The antioxidant activity of the compounds was assayed by measuring scavenging of 1,1-diphenyl-2-picrylhydrazyl (DPPH) free radicals. In this experiment, different concentrations (10, 20, 40, 80 , and 200 μg mL −1 ) of each compound were prepared in methanol. Then, working solutions were mixed with 100 μL 160 μM methanol solution of DPPH. The reaction mixture was thoroughly mixed for 2 min. The samples were then incubated for 30 min in the dark at 35°C. After incubating for 30 min, the absorbance of the samples was measured spectroscopically at 517 nm using a TRIAD multimode reader. In this experiment, ascorbic acid was used as positive control and methanol solution as a negative control. The radical scavenging potential is expressed as an EC 50 value, representing the compound concentration at which 50% of the DPPH radicals was scavenged. All tests were performed in triplicate, and values are presented as means. The ability of the compound to scavenge the formation of DPPH free radicals was measured in a concentration-dependent manner and the DPPH scavenging activity calculated in terms of the effective concentration.
In-vitro antifungal studies by broth dilution method
The antifungal activity of the compounds was determined by broth dilution method using p-iodonitrotetrazolium Ethical approval: The conducted research is not related to either human or animal use.
Results and discussion

Chemistry
In the present work, a series of 3,4-dihydro-9-arylacridin-1(2H)-one based enaminones and their derivatives were synthesized. In the first step different benzophenone derivatives (1a-c) were converted into their corresponding 3,4-dihydro-9-arylacridin-1(2H)-ones (2a-c) by treating them with 1, 3-cyclohexanedione (Scheme) in ethanol in the presence of ortho-phosphoric acid as a catalyst. The obtained products 2a-c were further treated with DMFDMA catalyst to form corresponding enaminones (3a-c) under the conventional heating method, in which different solvents such as DMF, xylene, toluene, acetonitrile and dioxane were examined for the effective conversion of 2a-c to 3a-c (Scheme). The yield was observed to be better with toluene and hence, toluene was considered as a suitable solvent for this reaction (Table-1 ). All the newly formed enaminones 3a-c were characterized using 1 H-NMR, 13 C-NMR, DEPT-135, H, H-COSY, HSQC, HR-MS (ESI) and the detailed data included in the experimental part.
The above enaminone derivatives (3a-c) afford various cyclized derivatives of 3,4-dihydro-9-arylacridin-1(2H)-ones such as 4a-c, 5a-c, and 6a-c (Scheme) while it is treated with reagents such as hydrazine, hydroxylamine hydrochloride and phenylhydrazine. All these newly synthesized compounds were characterized using 1 H-NMR, 13 C-NMR, DEPT-135, H, H-COSY, HSQC, HR-MS (ESI) and the data included in the experimental section. Consequently, all the newly derived compounds 3a-c, 4a-c, 5a-c and 6a-c were subjected to the antifungal, antibacterial and anti-oxidant evaluations and their results are discussed under biological evaluation.
Biological evaluations
In-vitro antifungal activity
The antifungal activity of the compounds is presented in terms of MIC in Table- 2. These minimum inhibitory concentration values demonstrate that the compounds exhibited good to moderate antifungal activity against the tested fungal pathogens. Among the compounds, 3a and 6a showed the highest antifungal activity with MIC value 0.007 and 0.006 μM against Candida albicans and Aspergillus niger respectively. In the case of Candida parapsilosis, promising antifungal activity was observed for compounds 3a, 5a and 6a with MIC values such as 0.028, 0.031 and 0.023 μM respectively. In the case of Aspergillus niger, compound 6a showed good antifungal activity as compared with positive control miconazole with MIC value of 0.006 μM. In the case of Candida glabrata, compound 4a exhibited good antifungal activity with MIC value 0.031 μM. The other compounds such as 4b, 5b-c and 6b-c failed to exhibit the activity against the all the fungal pathogens tested and hence not included in Table- 2. The compound which showed lower antifungal activity is due to substitution on benzene ring, whereas compound 3a, 4a and 6a has no such substitution and hence exhibiting better activity. The results demonstrate that the compounds possess good antifungal activity against the fungal pathogens. Among all the compounds, the compounds 3a and 6a exhibited considerable fungal activity (MIC value as 0.89 μM) against Candida albicans MTCC 227 and Aspergillus niger MTCC 1344 respectively. Whereas other compounds, the anti-fungal activity is lower than 3a and 6a due to substitution on the aryl ring but in 3a and 6a there is no substitution on it.
In-vitro antibacterial activity
The compounds exhibited promising broad-spectrum antibacterial activity against the tested Gram-positive and Gram-negative bacteria pathogens. The antibacterial activity of the compounds is presented in terms of minimum inhibitory concentration in standard neomycin (MIC 0.030 μM), compound 3a and 4a exhibited the highest antibacterial activity with MIC of 0.007 and 0.007 μM. This data clearly suggests that the compounds exhibit promising broad-spectrum antibacterial activity against test bacterial pathogens. The compound 4a showed excellent antibacterial activity towards Escherichia coli MTCC 1687 (MIC value 0.003 μM). The other compounds such as 3c, 4b, 5b-c and 6b failed to exhibit the activity against the all the bacterial pathogens tested and hence are not included in Table-3 . The compound which showed lower antibacterial activity is due to substitution on the aryl ring, whereas in compounds 3a, 4a and 6a has no such substitution and hence exhibiting better activity.
The data clearly suggested that the compounds exhibit promising broad-spectrum of antibacterial activity against test bacterial pathogens. The compound 4a showed excellent antibacterial activity towards Escherichia Coli MTCC 1687 (MIC value 0.003 μM). Whereas other compounds, the anti-bacterial activity is low due to substitution on benzene ring but in compound 4a there is no substitution on it.
In-vitro antioxidant activity
The results of free radical-scavenging capacity of the compounds by DPPH methods are shown in Table- 4. All of the compounds except 3c, 4b and 5b-c demonstrated inhibitory activity against the DPPH free radicals. The order of free radical-scavenging capacity of the compounds was 5a>4a>3a>6b>6a>4c = 3b>6c. The compounds 4a and 5a showed the highest free radical-scavenging capacity as compared to standard ascorbic acid with EC 50 values 18.9 ± 1.9 and 16.85 ±1.5μgmL -1 respectively. 
Conclusion
The 3,4-dihydro-9-arylacridin-1(2H)-one based enaminones was successfully synthesized by exploring the synthetic potential of DMFDMA which in turn converted into number of biologically potent heterocycles. In addition all the newly synthesized compounds were subjected to the in-vitro antifungal, antibacterial and antioxidant evaluations to find their efficacy and the potent lead molecules were found.
